Bio-Thera Solutions Unveils New Innovations with BAT1006 at 2023 AACR Annual Meeting

Bio-Thera Solutions, Ltd. (SH: 688177) is set to present a poster at the 2023 AACR Annual Meeting in Orlando, Florida, featuring Phase 1 clinical results for its promising BAT1006 drug. This commercial-stage pharmaceutical company is developing a potential breakthrough treatment for cancer and hopes to gain further insight from this poster presentation.

Attendees of the conference will have the opportunity to get an in-depth look at this exciting new development in the fight against cancer.

AACR will host a poster presentation on BAT1006, a novel anti-HER2 antibody, providing Phase I clinical data on its safety and efficacy in HER2-positive cancer patients. Get an exclusive insight into the promising results of this study when the abstract is made available on their website the day of the presentation. Don’t miss this opportunity to discover how BAT1006 has been making a positive impact in the fight against cancer.

About BAT1006

BAT1006 is a revolutionary monoclonal antibody that targets the extracellular domain II of the HER2 protein with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) capabilities. This cutting-edge therapy has the potential to revolutionize the treatment of HER2-positive locally advanced and metastatic solid tumors.

After the successful completion of its dose escalation trial, BAT1006 is to be further evaluated in a dose expansion study, as well as in combination with other HER2-based therapies such as BAT8010 ADC. With this promising new therapy, we are one step closer to conquering HER2-positive cancers.

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a pioneering biopharmaceutical company based in Guangzhou, China, is on a mission to develop innovative therapeutics and biosimilars to treat a range of cancer, autoimmune and other severe diseases.

With cutting-edge technology in antibody discovery and engineering, the company has three approved products (QLETLI®, POBEVCY® and BAT1806) and 25 candidates in clinical trials. Its focus is on immuno-oncology in the post-PD-1 era and targeted therapies such as ADCs, all of which show great promise for treating unmet medical needs.

Leave a Comment